XORTX Announces US$5 Million Public Offering

About this update from Xortx Therapeutics, Inc.

[{"type":"text","content":"XORTX Announces US$5 Million Public Offering\nCALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the pricing of a public offering of 2,659,574 common shares (“Common Shares”) or common shares equivalents in lieu thereof (“Pre-Funded Warrants”) at an offering price of US$1.88 for gross proceeds of US$5 million, prior to deducting placement agent’s fees and other offering expenses (the “Offering”). The Pre-Funded Warrants have an exercise price of US$0.0001 per share, will be immediately exercisable, and will terminate once exercised in full. The Offering is expected to close on or about May 15, 2026, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. E.F. Hutton & Co. is acting as exclusive placement agent for the Offering. The securities described above are being offered pursuant to a registration statement on Form F-1 (File No. 333-290512), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on May 13, 2026. The Offering is being made only by means of the prospectus forming part of the effective registration statement relating to the Offering. A final prospectus relating to the Offering will be filed with the SEC. Copies of the final prospectus relating to the Offering may be obtained, when available, by contacting E.F. Hutton & Co., 745 Fifth Avenue, 34th Floor and PH, New York, NY 10151, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at https://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About XORTX Therapeutics Inc. XORTX is a pharmaceutical com...

More updates from Xortx Therapeutics, Inc.